Healthcare
Live Price
Offline$9.65
-2.53% today
1Y Change
-41.76%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ARS Pharmaceuticals, Inc. (SPRY) is a Healthcare stock with a market cap of $850.00M and listed on NASDAQ. The stock last traded around $9.65 and down 41.8% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -5.5%, EPS growth of -2209.1%, a dividend yield of 0.0%. What stands out right now is revenue -5.5%, EPS -2209.1%, free cash flow -1418.5% with operating margin -212.9% and ROIC -62.0%. Valuation already assumes a fairly strong business story at price/sales 10.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SPRY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SPRY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SPRY Max Drawdown
-63.32%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SPRY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$5.5M
+318.4% YoY
FY Net Income
-$20.2M
+41.6% YoY
Free Cash Flow
-$17.6M
+56.3% YoY
Revenue Growth
-5.5%
EPS Growth
-2209.1%
Gross Margin
75.8%
Net Margin
-203.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 84M | 89M | 30K | 1M | 6M |
| Gross Profit | 64M | 69M | 30K | -16M | 5M |
| Operating Income | -179M | -3M | -68M | -36M | -19M |
| EBITDA | -178M | -3M | -67M | -35M | -19M |
| Net Income | -171M | 8M | -54M | -35M | -20M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 41M | 51M | 71M | 211M | 60M |
| Total Assets | 328M | 351M | 233M | 281M | 61M |
| Total Liabilities | 213M | 94M | 2M | 9M | 93M |
| Shareholder Equity | 114M | 257M | 231M | 273M | -31M |
| Total Debt | 97M | 42K | 274K | 481K | 9M |
| Net Debt | 56M | -51M | -71M | -210M | -51M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
18M
+56.2% YoY
Capital Expenditures
55K
+72.4% YoY
Free Cash Flow
18M
+56.3% YoY
Key ratios
Gross Margin
75.8%
Operating Margin
-212.9%
Net Margin
-203.3%
ROE
-100.3%
Debt / Equity
0.85x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.